Effectiveness of the monovalent influenza A(H1N1)2009 vaccine in Navarre, Spain, 2009-2010: cohort and case-control study.

Autor: Castilla J; Instituto de Salud Pública de Navarra, Pamplona, Spain. jcastilc@navarra.es, Morán J, Martínez-Artola V, Fernández-Alonso M, Guevara M, Cenoz MG, Reina G, Alvarez N, Arriazu M, Elía F, Salcedo E, Barricarte A
Jazyk: angličtina
Zdroj: Vaccine [Vaccine] 2011 Aug 11; Vol. 29 (35), pp. 5919-24. Date of Electronic Publication: 2011 Jun 30.
DOI: 10.1016/j.vaccine.2011.06.063
Abstrakt: We defined a population-based cohort (596,755 subjects) in Navarre, Spain, using electronic records from physicians, to evaluate the effectiveness of the monovalent A(H1N1)2009 vaccine in preventing influenza in the 2009-2010 pandemic season. During the 9-week period of vaccine availability and circulation of the A(H1N1)2009 virus, 4608 cases of medically attended influenza-like illness (MA-ILI) were registered (46 per 1000 person-years). After adjustment for sociodemographic covariables, outpatient visits and major chronic conditions, vaccination was associated with a 32% (95% CI: 8-50%) reduction in the overall incidence of MA-ILI. In a test negative case-control analysis nested in the cohort, swabs from 633 patients were included, and 123 were confirmed for A(H1N1)2009 influenza. No confirmed case had received A(H1N1)2009 vaccine versus 9.6% of controls (p<0.001). The vaccine effectiveness in preventing laboratory-confirmed influenza was 89% (95% CI: 36-100%) after adjusting for age, health care setting, major chronic conditions and period. Pandemic vaccine was effective in preventing MA-ILI and confirmed cases of influenza A(H1N1)2009 in the 2009-2010 season.
(Copyright © 2011 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: